2. Signaling Pathways
  3. MAPK/ERK Pathway
  4. MAP4K
  5. MAP4K7/TNIK Isoform

MAP4K7/TNIK

MAP4K7/TNIK is a TRAF2- and NCK-interacting serine/threonine kinase that functions as a regulatory component of the β-catenin-TCF4 transcriptional complex[1]. Mechanistically, TNIK activates Wnt target genes and supports full canonical Wnt/β-catenin transcriptional output[1][2]. In colorectal cancer, TNIK acts downstream of APC loss, making it relevant to APC-mutant Wnt-dependent tumor models[3]. TNIK inhibition suppressed colorectal cancer growth, cancer stemness, and Wnt-driven intestinal tumorigenesis in preclinical models[4]. Compared with related GCK-IV kinases, MAP4K4, MINK1/MAP4K6, and TNIK/MAP4K7 act redundantly in neuronal stress-induced DLK/JNK signaling, so isoform-selective interpretation requires careful experimental design[5]. For experimental applications, NCB-0846, mebendazole-derived OBD9, and ATP-site TNIK inhibitors provide tools to test Wnt transcription, colorectal cancer stemness, EMT, and inhibitor-binding mechanisms[4][6][7][8].

MAP4K7/TNIK Related Products (6):

Cat. No. Product Name Effect Purity
  • HY-100830
    NCB-0846
    		Inhibitor 99.61%
    NCB-0846 is an orally active, selective inhibitor for Wnt, that inhibits Traf2- and Nck-interacting kinase (TNIK) with an IC50 of 21 nM. NCB-0846 blocks TGF-β signaling pathway by inhibiting SMAD2/3 phosphorylation and nuclear translocation.
  • HY-111754
    DMX-5804
    		Inhibitor 99.83%
    DMX-5804 is a potent, orally active and selective MAP4K4 inhibitor, with an IC50 of 3 nM, a pIC50 of 8.55 for human MAP4K4, less potent on MINK1/MAP4K6 (pIC50, 8.18), and TNIK/MAP4K7 (pIC50, 7.96). DMX-5804 enhances cardiomyocyte survival, and reduces ischemia-reperfusion injury in mice.
  • HY-124745
    KY-05009
    		Inhibitor 99.88%
    KY-05009 is an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a Ki of 100 nM. KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells. KY-05009 inhibits the protein expression of TNIK and transcriptional activity of Wnt target genes and induces apoptosis in cancer cells. KY-05009 exerts anti-cancer activity.
  • HY-100830A
    NCB-0970
    		Control 98.81%
    NCB-0970 is the negative control of NCB-0846 (HY-100830). NCB-0846 is an orally active, selective inhibitor for Wnt, that inhibits Traf2- and Nck-interacting kinase (TNIK) with an IC50 of 21 nM. NCB-0846 blocks TGF-β signaling pathway by inhibiting SMAD2/3 phosphorylation and nuclear translocation.
  • HY-W402208
    MAP4K4-IN-7
    		Inhibitor
    MAP4K4-IN-7 (Compound 8) is a MAP4K4 inhibitor. MAP4K4-IN-7 shows moderate inhibitory activity against TNIK, MAP4K4, and MINK1 with pIC50 values of 6.8, 6.8, and 6.7 respectively. MAP4K4-IN-7 can be used for the researches of cancer and neurological disease, such as schizophrenia.
  • HY-183059
    TNIK-IN-11
    		Inhibitor
    TNIK-IN-11 is a TNIK inhibitor with a human TNIK pIC50 of 7.80. TNIK-IN-11 inhibits TNIK kinase activity and promotes neurite outgrowth. TNIK-IN-11 activates AKT signaling via increased phosphorylated AKT levels, and induces gene expression changes including upregulation of neuronal differentiation and morphological remodeling genes. TNIK-IN-11 can be used for the research of dup15q syndrome.